# Trade Mark Journal No.2026/013 27 March 2026

## UK00004348613 3 March 2026 (1,5,9,42,44)

Mark 1

Mark 2

Class 1
  Reagents and kits for research, industry and diagnostic purposes [not for medical or veterinary use]; Reagents and kits for medical research; Biological preparations for use in research, industry and science; human cells and isogenic cell lines for research or scientific purposes [not for medical or veterinary use].
Class 5
  Pharmaceuticals; pharmaceutical preparations, substances, and compounds for medical use; therapeutic drugs and agents; biotechnology preparations, substances and compounds for medical use; gene therapy products for medical use; reagents for use in medical testing; reagents and testing kits for medical use; diagnostic reagents and kits for medical use.
Class 9
  Computer software; computer platform software; computer database software; computer software for data analysis and reporting; computer software for the sequencing, annotation, analysis, interpretation and reporting of genome data; computer software for potential patient identification, potential patient stratification and medical diagnosis; computer software for drug discovery and research; computer software for research and medical purposes; computer software for analysis of data relating to pharmaceutical development; computer databases; computer database servers; computer software for database management; computer software for creating searchable databases of information and data.
Class 42
  Research and development services; scientific research and development services; biotechnology research and development services; pharmaceutical research and development services; drug discovery; pharmaceutical drug development; research and development services in the field of bioinformatics; research and development services in the field of personalised medicine, precision medicine, stratified medicine or drug discovery; research and development in the field of immunology, drug target discovery, clinical trial design or medical diagnostics; research and development of pharmaceutical preparations and medicines; medical research and development services; design and development of databases; design and development of computer software; design and development of computer databases; design and development of computer software for services in the field of pharmaceuticals, clinical trials, personalised medicine and genetics; design and development of computer database for services in the field of pharmaceuticals, clinical trials, personalised medicine and genetics; providing computer software and databases as a service for genome sequencing, annotation, interpretation and reporting; providing software and databases as a service for drug discovery and research; providing software and databases as a service for potential patient identification, potential patient stratification or medical diagnosis; providing software and databases as a service for research and medical purposes; information, advisory and consultancy services in relation to all of the aforesaid; cell-line engineering services; gene-editing services; consultancy, advisory and/or information services relating to or connected with the aforementioned services.
Class 44
  Analysis of data for medical and health purposes; medical testing; providing information, advice and data relating to genetics and pharmaceuticals for medical and health purposes; pharmaceutical services; medical and health services relating to DNA, genetics and genetic.

Nucleome Therapeutics Limited

Representative: Mathys & Squire LLP